Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Late-onset Neonatal Sepsis
NCT01294865 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2011-02-14
Summary
The purpose of the study is to investigate the plasma levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) at the diagnosis and after treatment of sepsis, and to determine whether it has a diagnostic and prognostic value in late-onset neonatal sepsis.
Conditions
- Neonatal Sepsis
Sponsors & Collaborators
-
Ankara University
lead OTHER
Principal Investigators
-
Saadet Arsan, Professor · Ankara University
Eligibility
- Min Age
- 4 Days
- Max Age
- 1 Month
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-01-31
- Primary Completion
- 2012-01-31
- Completion
- 2012-06-30
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
Genotypes and Phenotypes in Pediatric SIRS and Sepsis
NCT02728401 ·Status: COMPLETED
-
Rituximab in the First Episode of Paediatric Nephrotic Syndrome
NCT05850546 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
NCT05630612 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis
NCT05101447 ·Status: WITHDRAWN ·Phase: PHASE2
-
To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN
NCT00302549 ·Status: COMPLETED ·Phase: NA
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
NCT06788691 ·Status: RECRUITING ·Phase: PHASE2
-
Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
NCT02592798 ·Status: COMPLETED ·Phase: PHASE2
-
Cyclosporine Adverse Outcomes in Steroid Dependent and Frequent Relapsing Nephrotic Syndrome in Children;Single Center Study
NCT05588869 ·Status: UNKNOWN
-
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT07160608 ·Status: RECRUITING ·Phase: PHASE2
-
Cytokines in Blister Fluids of Bullous Pemphigoid (BP)
NCT03856840 ·Status: COMPLETED
-
Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens
NCT01275274 ·Status: WITHDRAWN ·Phase: PHASE2
-
Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
NCT00991146 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome
NCT04402580 ·Status: TERMINATED ·Phase: PHASE2
-
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
NCT03323476 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
NCT01302860 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics of Cyclosporin in Nephrotic Syndrome
NCT01616446 ·Status: COMPLETED
-
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
NCT05767047 ·Status: RECRUITING ·Phase: PHASE3
-
MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN
NCT05495893 ·Status: UNKNOWN ·Phase: PHASE4
-
Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
NCT03942887 ·Status: RECRUITING ·Phase: PHASE3
-
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
NCT06868290 ·Status: RECRUITING ·Phase: PHASE2
-
Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema
NCT02670720 ·Status: TERMINATED ·Phase: PHASE3
-
Stratified Therapy on Pediatric AAGN
NCT05969522 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
NCT04889430 ·Status: COMPLETED ·Phase: PHASE3
-
Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome
NCT03501459 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients
NCT00228020 ·Status: COMPLETED ·Phase: PHASE3